RxDoctor Payments Data

Samantha Hughes

Family · Santa Rosa, CANPI 1578135679

Payments from drug & device makers

$4,964in general payments, 2019–2025

Across 137 payments — averaging $36.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$1K
  • Amgen$892
  • Novartis$234
  • Pfizer$107
  • Aurinia Pharma U.S., Inc.$79
  • plus $343 from 9 others

What the payments were for

  • Consulting fees$1,32027%
  • Travel & lodging$752%
  • Food & beverage$3,51571%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,964 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$108,494
Medicare patients
247
Services billed
2,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab45$388,397
Enbrel SureclickEtanercept33$268,130
Cosentyx Sensoready PenSecukinumab26$206,491
Orencia ClickjectAbatacept36$201,014
Cosentyx Sensoready (2 Pens)Secukinumab23$180,545
Xeljanz XrTofacitinib Citrate19$149,740
Cosentyx (2 Syringes)Secukinumab13$94,297
SimponiGolimumab14$82,922
RinvoqUpadacitinib11$74,281
OtrexupMethotrexate/Pf15$24,231
Hydroxychloroquine Sulfate199$12,332
Leflunomide114$5,387
Cevimeline Hcl27$3,618
Prednisone326$3,000
Sulfasalazine DrSulfasalazine91$2,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$234$94,29713 claims
AbbVieRinvoq$1,336$74,28111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →